JP2009536651A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536651A5
JP2009536651A5 JP2009509820A JP2009509820A JP2009536651A5 JP 2009536651 A5 JP2009536651 A5 JP 2009536651A5 JP 2009509820 A JP2009509820 A JP 2009509820A JP 2009509820 A JP2009509820 A JP 2009509820A JP 2009536651 A5 JP2009536651 A5 JP 2009536651A5
Authority
JP
Japan
Prior art keywords
cyclobutyl
diazaspiro
undecane
undes
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009509820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536651A (ja
Filing date
Publication date
Priority claimed from US11/745,448 external-priority patent/US20080247964A1/en
Application filed filed Critical
Publication of JP2009536651A publication Critical patent/JP2009536651A/ja
Publication of JP2009536651A5 publication Critical patent/JP2009536651A5/ja
Withdrawn legal-status Critical Current

Links

JP2009509820A 2006-05-08 2007-05-08 置換されたアザスピロ誘導体 Withdrawn JP2009536651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74668006P 2006-05-08 2006-05-08
US11/745,448 US20080247964A1 (en) 2006-05-08 2007-05-07 Substituted azaspiro derivatives
PCT/US2007/011135 WO2007133561A2 (en) 2006-05-08 2007-05-08 Substituted azaspiro derivatives

Publications (2)

Publication Number Publication Date
JP2009536651A JP2009536651A (ja) 2009-10-15
JP2009536651A5 true JP2009536651A5 (enExample) 2010-07-01

Family

ID=38694439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509820A Withdrawn JP2009536651A (ja) 2006-05-08 2007-05-08 置換されたアザスピロ誘導体

Country Status (8)

Country Link
US (1) US20080247964A1 (enExample)
EP (1) EP2021004A4 (enExample)
JP (1) JP2009536651A (enExample)
KR (1) KR20090015956A (enExample)
AU (1) AU2007249925A1 (enExample)
CA (1) CA2651654A1 (enExample)
IL (1) IL195132A0 (enExample)
WO (1) WO2007133561A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
EP2569294B1 (en) 2010-05-11 2015-03-11 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR081908A1 (es) 2010-05-11 2012-10-31 Sanofi Aventis N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたn−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
WO2011143161A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたn−アルキルおよびn−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
HK1208681A1 (en) * 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2014006945A1 (ja) 2012-07-04 2014-01-09 アグロカネショウ株式会社 2-アミノニコチン酸エステル誘導体およびこれを有効成分とする殺菌剤
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CN103288845B (zh) * 2013-05-24 2015-05-20 武汉工程大学 螺环化合物2,4,8,10-四羰基-3,9-二氧杂螺环[5,5]十一烷及其合成方法
CN105636953B (zh) * 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
DK3119782T3 (en) * 2014-03-17 2018-03-12 Remynd Nv Bio Incubator 2,7-diazaspiro [3.5] NONANFORBINDELSER
CA2964103C (en) 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) * 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
WO2018068296A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
KR20210102887A (ko) * 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH375356A (de) * 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
US3106552A (en) * 1960-07-19 1963-10-08 Geschickter Fund Med Res Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
US5451578A (en) * 1994-08-12 1995-09-19 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
GB2309167A (en) * 1997-05-10 1997-07-23 Anormed Inc The use of azaspiranes in the treatment of Alzheimer's disease
ES2162503T3 (es) * 1998-06-12 2001-12-16 Hoffmann La Roche Derivados diaza-espiro(3,5)nonanos.
PT1519939E (pt) * 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização
MXPA05009708A (es) * 2003-03-10 2006-05-25 Callisto Pharmaceuticals Inc Metodo para el tratamiento de cancer con composiciones de azaspirina.
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
WO2005047286A1 (ja) * 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
JP2008510711A (ja) * 2004-08-20 2008-04-10 ターガセプト,インコーポレイテッド 嗜癖治療におけるn−アリールジアザスピラ環状化合物の使用
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP2008546826A (ja) * 2005-06-28 2008-12-25 ノイロサーチ アクティーゼルスカブ 新規な3,9−ジアザ−スピロ[5.5]ウンデカン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのこれらの使用
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Similar Documents

Publication Publication Date Title
TWI868441B (zh) 非環氧氮呯化合物及其用途
US12030883B2 (en) Hetero-tricyclic compounds as inhibitors of KRAS
US11931363B2 (en) Triazolopyrimidine compounds and uses thereof
AU2020276802B2 (en) Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
JP6574859B2 (ja) Atrキナーゼ阻害剤として有用な化合物
JP2014506929A5 (enExample)
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
ES2398843T3 (es) Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
BR112012010820B1 (pt) Compostos de octa-hidropirrolo[3,4-c]pirróis dissubstituídos, suas composições farmacêuticas e seu uso
WO2017223414A1 (en) HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
EP3472166A1 (en) Imidazopyrimidine compounds useful for the treatment of cancer
JP2015522002A5 (enExample)
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
JP2016538316A5 (enExample)
JP2010512338A5 (enExample)
KR20150108389A (ko) 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법
US20250002507A1 (en) 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders
KR20090015956A (ko) 치환된 아자스피로 유도체
JP2013256532A (ja) キナーゼインヒビターとして有用なアミノピリミジン
US20250230155A1 (en) 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders
IL323963A (en) 1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 useful for the treatment of neurological and psychiatric disorders
WO2025103475A1 (zh) 杂环羰基类衍生物调节剂、其制备方法和应用
ES2278345T3 (es) Imidazo-pirimidinas y triazolo-pirimidinas: ligandos de receptores de benzodiazepinas.
JP2023519361A5 (enExample)